Bristol Myers Squibb (BMY)
(Delayed Data from NYSE)
$48.11 USD
+0.49 (1.03%)
Updated Aug 23, 2024 04:00 PM ET
After-Market: $48.10 -0.01 (-0.02%) 7:58 PM ET
3-Hold of 5 3
B Value B Growth A Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$48.11 USD
+0.49 (1.03%)
Updated Aug 23, 2024 04:00 PM ET
After-Market: $48.10 -0.01 (-0.02%) 7:58 PM ET
3-Hold of 5 3
B Value B Growth A Momentum A VGM
Zacks News
New York-based Bristol-Myers Squibb is a one of the leading global specialty bio-pharmaceutical companies focused on the development of treatments targeting serious diseases. Backed by its blockbuster immune-oncology drug, Opdivo, Bristol-Myers has a strong oncology portfolio, consisting of other drugs like Revlimid, Sprycel, Yervoy and Empliciti. Beyond oncology, the company has important immunology and cardiovascular drugs like Orencia and Eliquis, which diversify its portfolio. Notably, in the cardiovascular space, Eliquis is now the global leading oral anti-coagulant drug. The company continues to experience growth in both the Eliquis brand and the market, while also advancing its Factor XIa inhibitor program..
ARIAD Stock Beats Industry in 2016, Iclusig Sales Strong
by Zacks Equity Research
Shares of ARIAD Pharma surged 98.4% year to date and outperformed the Zacks classified Medical-Drugs industry that declined 25.4%.
AbbVie's Humira and Imbruvica Drive Performance in 2016
by Zacks Equity Research
AbbVie Inc.'s (ABBV) share price is up 5.9% so far this year.
Pharma Stock Roundup: Cempra Plunges to 52-Week Low, Shire Drug Label Expanded
by Arpita Dutt
Key highlights this week include complete response letters from the FDA for a couple of companies with Cempra (CEMP) plunging to a 52-week low.
Portola Betrixaban Accepted for Review in U.S. & EU, Stock Up
by Zacks Equity Research
Shares of Portola (PTLA) surged 33.8% after the FDA granted priority review to anticoagulant, betrixaban. Betrixaban was also accepted by the EMA for review.
Pharma Stock Roundup: J&J Back in Talks with Actelion, Teva Settles Corruption Probe
by Arpita Dutt
J&J (JNJ) and Actelion are back in the limelight with the companies in exclusive talks regarding a possible deal.
Bristol-Myers, Calithera Team Up for Opdivo/CB-839 Combo
by Zacks Equity Research
Bristol-Myers Squibb Company (BMY) announced a clinical trial collaboration with Calithera Biosciences, Inc. (CALA).
Bristol-Myers, PsiOxus Ink Deal for Oncolytic Virus Therapy
by Zacks Equity Research
Bristol-Myers (BMY) inks a deal with PsiOxus for an early-stage oncolytic virus candidate, NG-348.
The Zacks Analyst Blog Highlights: Bristol-Myers, Shell, Facebook, Baker Hughes, Eli Lilly and Fifth Third Bancorp
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Bristol-Myers, Shell, Facebook, Baker Hughes, Eli Lilly and Fifth Third Bancorp
Pharma Stock Roundup: Drug Pricing Heat Back on Sector, Endo, Mylan, AZN to Cut Jobs
by Arpita Dutt
Drug pricing is back in focus with president-elect Trump making it clear that he does not like price increases.
Bristol-Myers Reports Data from Opdivo Combination Studies
by Zacks Equity Research
Bristol-Myers (BMY) presented multiple data from Opdivo combination studies.
Pharma Stock Roundup: Nivalis Falls on Study Data, Priority Reviews for Merck's Keytruda
by Arpita Dutt
This week, companies like Merck (MRK) and Pfizer (PFE) provided updates on their pipelines.
Heat Biologics Stock Falls on Negative Bladder Cancer Data
by Zacks Equity Research
Heat Biologics (HTBX) presented disappointing top-line phase II data from the bladder cancer study on its lead pipeline candidate, HS-410.
ARIAD's Leukemia Drug Iclusig Gets Full Approval in U.S.
by Zacks Equity Research
ARIAD Pharmaceuticals, Inc. (ARIA) announced that the FDA has granted a full approval to its leukemia drug, Iclusig (ponatinib), following its successful completion of the commitments made on accelerated approval in Dec 2012.
The Zacks Analyst Blog Highlights: Bristol-Myers, Google, Deere, Halliburton and American Airlines
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Bristol-Myers, Google, Deere, Halliburton and American Airlines
Zacks Industry Outlook Highlights: Bristol-Myers, Biogen, Merck, Celgene and ARIAD Pharmaceuticals
by Zacks Equity Research
Zacks Industry Outlook Highlights: Bristol-Myers, Biogen, Merck, Celgene and ARIAD Pharmaceuticals
Stock Market News for August 10, 2016
by Zacks Equity Research
Benchmarks closed narrowly in the green as drop in oil prices and disappointing productivity data offset some of the gains in healthcare and consumer staples stocks
Stock Market News for August 09, 2016
by Zacks Equity Research
Despite strong crude rally, major benchmarks closed in the red on Monday on the back of declines in healthcare stocks
BLS Reports Robust July Jobs: 255K, 4.9% Unemployment
by Mark Vickery
Also, May's paltry 11K jobs was more than doubled to 24K, and even June's strong 287K rose another 5000 jobs to 292K.
Bull of the Day: Bristol-Myers Squibb (BMY)
by Neena Mishra
This specialty pharma giant is a leader in innovative cancer treatments.
Don't Make It Complicated, Own Drug Stocks
by John Blank
The basic ingredients for rising drug demand -- the frailties that accompany aging -- are going to be there for the next 2 decades, in the USA and elsewhere.